冠心病患者血脂异常与胰岛素抵抗的关系

目的 :探讨冠心病患者血脂异常与胰岛素抵抗的关系。方法 :观察 68例冠心病患者与 66例对照者的血脂、血糖、胰岛素等生化指标 ,以胰岛素释放指数———空腹胰岛素 (FIns) /空腹血糖 (FBG)和胰岛素敏感指数(1 /FBG×FIns)作为胰岛素抵抗 (IR)的指标 ,与空腹血脂进行直线相关分析。结果 :冠心病组与对照组对比 ,血糖水平无明显差异 (P >0 .0 5) ,而血胰岛素、胰岛素释放指数明显较对照组增高 (P <0 .0 5) ,胰岛素敏感指数明显较对照组低 (P <0 .0 5)。冠心病组的甘油三酯 (TG)、总胆固醇 (TC)、低密度脂蛋白胆固醇 (LDL -C)明显较对照组增高 (P <0 .0 5)、高密度脂蛋白胆固醇 (HDL -C)明显较对照组低 (P <0 .0 5)。冠心病组胰岛素释放指数、胰岛素敏感指数分别与TG ,TC和LDL -C呈正相关 ,与HDL -C呈负相关。结论 :冠心病患者存在着高胰岛素血症和胰岛素抵抗 ,而且冠心病患者的胰岛素抵抗和血脂异常密切相关。     

糖尿病调脂药物治疗的循证医学

本文重点介绍近年来糖尿病患者调脂治疗,主要包括临床常用的他汀类、贝特类、烟酸等药物降胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白-胆固醇(LDL-C)水平、升高高密度脂蛋白-胆固醇(HDL-C),以及减少心血管事件的疗效、不良反应等。     

血脂康对急性冠状动脉综合征患者血清高敏C-反应蛋白、血脂蛋白的影响

目的观察急性冠状动脉综合征(ACS)患者血清高敏C-反应蛋白(Hs-CRP)、血脂水平变化及血脂康的干预情况。方法69例ACS患者随机分为血脂康组(40例)和常规治疗组(29例),治疗前后分别测定Hs-CRP、总胆固醇、甘油三酯、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C);另30名健康人为对照组。结果与对照组比较,ACS患者Hs-CRP水平明显升高,且与心肌损害程度密切相关。血脂康治疗2周,能明显下调ACS患者的Hs-CRP水平。结论血清Hs-CRP水平与ACS的发生、严重程度密切相关,血脂康的抗炎作用在ACS的早期治疗中有重要意义。     

Neuroendocrine and clinical effects of transdermal 17β-estradiol in postmenopausal women

The neuroendocrine and clinical effects of transdermal 17β-estradiol (rated at 50 μg/day; TTS 50) were studied in 40 postmenopausal women; ten additional postmenopausal women did not receive any drugs. The changes in LH and rectal temperature induced by the infusion of the opioid antagonist naloxone (10 mg i.v. bolus plus 10 mg/h for 4 h) were used to evaluate the central activity of endogenous opioid peptides. TTS 50 increased opioid activity, as evidenced by the restoration of the LH response (P < 0.01) and the enhancement of the hypothermic effect (P < 0.05) of naloxone. A greater reduction in hot flushes was observed in TTS 50-treated subjects than in untreated women, with the maximal effect of TTS 50 achieved after 3 months of therapy. TTS 50 did not modify the concentrations of circulating lipids, glucose or liver enzymes but reduced the biochemical parameters indicative of bone reabsorption. Bone density of the distal radius significantly increased during TTS 50 (P < 0.02), reaching its maximum value after 6 months of therapy. Thereafter bone density declined, but more slowly than in untreated women.

Our data suggest that TTS 50 has marked neuroendocrine effects, that it diminishes the incidence of hot flushes and reduces bone demineralization. By contrast, it has a very little, if any, metabolic impact on the liver or on glucose and lipid metabolism.     

2型糖尿病患者胆结石发生的高危因素分析

目的：探讨2型糖尿病患者胆结石与高胰岛素、脂代谢紊乱的关系。方法：采用病例对照研究的方法，观察50例伴胆结石与60例不伴胆结石的2型糖尿病患者血清胰岛素、胰岛素敏感指数、C肽、血脂的变化。结果：发现伴胆结石患者的血清胰岛素、C肽、甘油三酯、胆固醇显著高于不伴胆结石组（P＜0．05），高密度脂蛋白、胰岛素敏感指数显著低于不伴胆结石组（P＜0．05），载脂蛋白－A1明显降低（P＜0．01），而两组低密度脂蛋白、脂蛋白－a、载脂蛋白－B1无差异。结论：高胰岛素血症、脂代谢异常可能中老年2型糖尿病患者胆结石 形成的高危因素。     

Pharmacology of the AC AT Inhibitor Avasimibe (CI‐1011)

Avasimibe is a novel orally bioavailable ACAT inhibitor, currently under clinical development (phase III trials). It was safe when administered to rats, dogs, and humans. In vitro studies in human macrophages demonstrated that avasimibe reduces foam cell formation not only by enhancing free cholesterol efflux, but also by inhibiting the uptake of modified LDL. The concentration‐dependent reduction in cellular cholesteryl ester content in these cells was not accompanied by an increase in intracellular free cholesterol, which is in agreement with a good safety profile for avasimibe. In the liver, avasimibe caused a significant reduction in the secretion of apo B and apo B‐containing lipoproteins into plasma. Avasimibe induced cholesterol 7α‐hydroxylase and increased bile acid synthesis in cultured rat hepatocytes, and its administration to rats did not produce an increase in lithogenicity index of the bile. The hypolipidemic efficacy of the compound was demonstrated in cholesterol‐fed as well as in non‐cholesterol‐fed animals. In these models, plasma cholesterol levels were reduced, mainly due to the decrease in the non‐HDL cholesterol fraction. Clinical data are scarce, but in a study performed in 130 men and women with combined hyperlipidemia and hypoalphalipoproteinemia, avasimibe, 50–500 mg/day, significantly reduced plasma total triglyceride and VLDL‐cholesterol. Although total cholesterol, LDL‐cholesterol, and HDL‐cholesterol were unchanged, it must be stressed that animal data suggest that avasimibe may have direct antiatherosclerotic activity in addition to its cholesterol‐lowering effect. Avasimibe treatment can also contribute to increase plaque stability, as it reduces the accumulation of lipids in the arterial wall, inhibits macrophage infiltration into the media and reduces matrix metalloproteinase expression and activity. Moreover, avasimibe and statins have been shown to have synergistic effects, and the combination therapy may not only inhibit atherosclerotic lesion progression but also induce lesion regression, independently of changes in plasma cholesterol.     

角质层及其类脂对雌二醇经皮渗透的作用

采用扩散装置和放射性同位素标记物测定,辅以FTIR和DSC技术,研究了雌二醇(OE)在角质层、去脂角质层、表皮以及活性表皮中的渗透性质和分配性质,分析角质层及其类脂在亲脂性药物经皮渗透中的作用。实验表明角质层是该类药物渗透的屏障,OE在其中的渗透速度受到角质层通透性和药物在角质层分配系数的双重控制,而OE从角质层转运至活性表皮的过程不成为限速因素。角质层的屏障性质仅部分来源于角质层类脂,而角质层细胞膜产生的阻力则是角质层屏障性质的重要组成部分。角质层类脂同时又可能是OE扩散的途径,该类物质通过对亲脂性药物增溶、提高后者在角质层中的分配产生影响。促进剂1,8-桉油精(1,8-CN)对OE的促渗作用也部分地依赖于角质层类脂的存在,通过一种可逆的物理相互作用改变类脂途径的通透性。     

Temporal stability of lipid responses to acute psychological stress in middle-aged men

The purpose of this study was to establish the temporal stability of lipid responses to acute psychological stress. Eighteen men were tested twice an average of 16.2 months apart in identical laboratory reactivity protocols. Total cholesterol, triglycerides, high- and low-density lipoprotein-cholesterol, plasma volume, heart rate, and blood pressure were assessed during rest, serial subtraction, and speech. After correction for changes in plasma volume, significant elevations were recorded for all variables during the speech task, but fewer variables showed changes during the serial subtraction task. Strong intersession associations were found when considering levels of the variables during baseline and stress (rs≥58). Correlations for the change scores ranged from .36 to .52 for the atherogenic lipids and from .39 to .87 for the cardiovascular variables. Little evidence was found for stability of plasma volume changes. There is moderate to high temporal stability of the atherogenic lipids when considering rest and stress levels and small to moderate temporal stability when considering change scores.     

Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolaemia

Abstract Familial hypercholesterolaemia is a genetic disorder characterised by high low-density lipoprotein (LDL) cholesterol concentrations, which frequently gives rise to premature coronary artery disease (CAD). The clinical expression of familial hypercholesterolaemia is highly variable even in patients carrying the same LDL receptor gene mutation. This variability may be due to environmental and other genetic factors. Apolipoprotein E (Apo-E) has been extensively studied for its effects on the phenotype of familial hypercholesterolaemia. In this study we examined the influence of Apo-E genotype on lipid parameters and the incidence of CAD in 93 Greek patients with familial hypercholesterolaemia. Apo-E E2, E3 and E4 allele frequencies were 0.06, 0.86 and 0.09 respectively. The levels of total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apolipoproteins A and B and lipoprotein α did not differ significantly among carriers and non-carriers of the E4 allele. The prevalence of CAD and hypertension did not differ either. Our results suggest that the E4 allele is not associated with lipid levels or with the prevalence of CAD among familial hypercholesterolaemia patients of the Greek population. *The two authors were equally involved in the work